Continuous infusion of vincristine-doxorubicin with bolus of dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 40, Issue 5-6, 2001, Pages 529-540

  Cartron, G ^a   Voillat, L ^a   Desablens, B ^a   Le Maignan, C ^a   Milpied, N ^a   Foussard, C ^a   Dugay, J ^a   Maakaroun, A ^a   De Muret, A ^a   Colombat, P ^a  

^a CHU BRETONNEAU   (France)

Author keywords

Elderly patient; IPI; Non Hodgkin's lymphoma; Phenotype; VAD

Indexed keywords

CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; B CELL LYMPHOMA; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART FAILURE; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATIENT REFERRAL; PERFORMANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; SURVIVAL RATE; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0035052944     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109097652     Document Type: Article

References (55)

1. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand lymphoma group
2. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
3. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non- Hodgkin's lymphoma
4. A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: A British national lymphoma investigation report
5. A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients
6. Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma
7. Chronological age is a multifactorial prognostic variable in patients with non-Hodgkin's lymphoma
8. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest oncology group experience
9. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project
10. Intermediate and high grade non Hodgkin's lymphoma in the elderly
11. Non-Hodgkin's lymphomas in 137 patients aged 70 years or older: A retrospective European organization for research and treatment of cancer Lymphoma group study
12. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma
13. Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose adriamycin- based regimens
14. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age
15. A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly
16. P-VEBEC: A new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL)
17. Non-Hodgkin's lymphoma in elderly patients: A phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate- or high-grade histology
18. P-VABEC: A prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma
19. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma
20. Low-dose ACOP-B and VABE: Weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma
21. A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma
22. Treatment of aggressive non-Hodgkin's lymphoma in aged patients with a combination of methyl-GAG, etoposide and prednimustine
23. Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: A phase II study
24. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma
25. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy
26. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma
27. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European organization for research and treatment cooperative study group
28. Effective treatment of advanced multiple myeloma refractory to alkylating agents
29. Reversal of multidrug resistance
30. Dependence of the cytostatic effect of adriamycin on drug concentration and exposure time in vitro
31. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma
32. VAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignancies
33. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy
34. Treatment of mantle-cell lymphomas with the VAD +/- chlorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantation
35. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The non-Hodgkin's lymphoma pathologic classification project
36. Report of the committee on Hodgkin's disease staging classification
37. The importance of dose intensity in the outcome of chemotherapy
38. Nonparametric estimation from incomplete observation
39. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
40. Regression models and life-tables
41. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy
42. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma
43. Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen
44. New treatment strategies for multiple myeloma
45. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro
46. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
47. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia
48. VAD-PECC regimen in the treatment of advanced-stage multiple myeloma
49. Elderly agressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen experience on 350 patients
50. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project
51. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen
52. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas
53. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma
54. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: The Stanford experience
55. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma